Erysipelas care episodes (n = 108) in Turku OPAT clinic; semi-structured electronic health record data, December 2020–January 2022
| . | Without eCIP . | With eCIP . |
|---|---|---|
| (n = 44) . | (n = 64) . | |
| Patient characteristics | ||
| Male, % | 47.7 | 56.3 |
| Age at care episode (years), median (range) | 72 (23–94) | 68 (30–95) |
| Comorbidities | ||
| Hypertension, % | 75.0 | 60.9 |
| Diabetes, % | 43.2 | 35.9 |
| Venous insufficiency, % | 25.0 | 21.9 |
| Arteriosclerosis obliteransa, % | 4.6 | 3.1 |
| Antibiotic allergy, % | 38.6 | 4.7 |
| Previous erysipelas infection, % | 45.5 | 48.4 |
| Prophylactic antibiotic, % | 9.1 | 7.8 |
| Care episode characteristics | ||
| CRPb (mg/l), median (range) | 117 (13–299) | 142 (8–435) |
| Blood culture positive infection (sepsis), % | 4.6 | 6.3 |
| Site of infection, % | ||
| lower extremity | 88.6 | 89.1 |
| upper extremity | 2.3 | 7.8 |
| other | 9.1 | 3.1 |
| Treated with penicillin, % | 15.9 | 90.6 |
| Clinical end result, % | ||
| Cured | 72.7 | 90.6 |
| Cured but unplanned changes in treatmentc | 22.7 | 6.3 |
| Treatment failure | 4.6 | 3.1 |
| Clinical end result at 3 months, % | ||
| Cured | 68.2 | 85.9 |
| Cured but unplanned changes in treatmentc | 5.6 | 1.6 |
| Treatment failure | 25.0 | 12.5 |
| Missing | 2.3 | – |
| Adverse event, % | ||
| Yes | 6.8 | 1.6 |
| No | 93.2 | 98.4 |
| . | Without eCIP . | With eCIP . |
|---|---|---|
| (n = 44) . | (n = 64) . | |
| Patient characteristics | ||
| Male, % | 47.7 | 56.3 |
| Age at care episode (years), median (range) | 72 (23–94) | 68 (30–95) |
| Comorbidities | ||
| Hypertension, % | 75.0 | 60.9 |
| Diabetes, % | 43.2 | 35.9 |
| Venous insufficiency, % | 25.0 | 21.9 |
| Arteriosclerosis obliteransa, % | 4.6 | 3.1 |
| Antibiotic allergy, % | 38.6 | 4.7 |
| Previous erysipelas infection, % | 45.5 | 48.4 |
| Prophylactic antibiotic, % | 9.1 | 7.8 |
| Care episode characteristics | ||
| CRPb (mg/l), median (range) | 117 (13–299) | 142 (8–435) |
| Blood culture positive infection (sepsis), % | 4.6 | 6.3 |
| Site of infection, % | ||
| lower extremity | 88.6 | 89.1 |
| upper extremity | 2.3 | 7.8 |
| other | 9.1 | 3.1 |
| Treated with penicillin, % | 15.9 | 90.6 |
| Clinical end result, % | ||
| Cured | 72.7 | 90.6 |
| Cured but unplanned changes in treatmentc | 22.7 | 6.3 |
| Treatment failure | 4.6 | 3.1 |
| Clinical end result at 3 months, % | ||
| Cured | 68.2 | 85.9 |
| Cured but unplanned changes in treatmentc | 5.6 | 1.6 |
| Treatment failure | 25.0 | 12.5 |
| Missing | 2.3 | – |
| Adverse event, % | ||
| Yes | 6.8 | 1.6 |
| No | 93.2 | 98.4 |
Data retrieved from semi-structured discharge summaries available since December 2020.
Peripheral artery disease.
CRP: C-reactive protein.
The patient was considered cured with unplanned changes in the antimicrobial treatment if the iv antibiotic had to be changed during OPAT or before the 3-month evaluation due to relapse of infection, adverse event, or other causes. There were only 4 patients with adverse events (Supplementary Appendix S5). One patient died, but the cause of death was not related to erysipelas or its treatment. No other causes or eCIP malfunctions were recorded. Therefore, most cases of unplanned changes represent relapses of infection.
Erysipelas care episodes (n = 108) in Turku OPAT clinic; semi-structured electronic health record data, December 2020–January 2022
| . | Without eCIP . | With eCIP . |
|---|---|---|
| (n = 44) . | (n = 64) . | |
| Patient characteristics | ||
| Male, % | 47.7 | 56.3 |
| Age at care episode (years), median (range) | 72 (23–94) | 68 (30–95) |
| Comorbidities | ||
| Hypertension, % | 75.0 | 60.9 |
| Diabetes, % | 43.2 | 35.9 |
| Venous insufficiency, % | 25.0 | 21.9 |
| Arteriosclerosis obliteransa, % | 4.6 | 3.1 |
| Antibiotic allergy, % | 38.6 | 4.7 |
| Previous erysipelas infection, % | 45.5 | 48.4 |
| Prophylactic antibiotic, % | 9.1 | 7.8 |
| Care episode characteristics | ||
| CRPb (mg/l), median (range) | 117 (13–299) | 142 (8–435) |
| Blood culture positive infection (sepsis), % | 4.6 | 6.3 |
| Site of infection, % | ||
| lower extremity | 88.6 | 89.1 |
| upper extremity | 2.3 | 7.8 |
| other | 9.1 | 3.1 |
| Treated with penicillin, % | 15.9 | 90.6 |
| Clinical end result, % | ||
| Cured | 72.7 | 90.6 |
| Cured but unplanned changes in treatmentc | 22.7 | 6.3 |
| Treatment failure | 4.6 | 3.1 |
| Clinical end result at 3 months, % | ||
| Cured | 68.2 | 85.9 |
| Cured but unplanned changes in treatmentc | 5.6 | 1.6 |
| Treatment failure | 25.0 | 12.5 |
| Missing | 2.3 | – |
| Adverse event, % | ||
| Yes | 6.8 | 1.6 |
| No | 93.2 | 98.4 |
| . | Without eCIP . | With eCIP . |
|---|---|---|
| (n = 44) . | (n = 64) . | |
| Patient characteristics | ||
| Male, % | 47.7 | 56.3 |
| Age at care episode (years), median (range) | 72 (23–94) | 68 (30–95) |
| Comorbidities | ||
| Hypertension, % | 75.0 | 60.9 |
| Diabetes, % | 43.2 | 35.9 |
| Venous insufficiency, % | 25.0 | 21.9 |
| Arteriosclerosis obliteransa, % | 4.6 | 3.1 |
| Antibiotic allergy, % | 38.6 | 4.7 |
| Previous erysipelas infection, % | 45.5 | 48.4 |
| Prophylactic antibiotic, % | 9.1 | 7.8 |
| Care episode characteristics | ||
| CRPb (mg/l), median (range) | 117 (13–299) | 142 (8–435) |
| Blood culture positive infection (sepsis), % | 4.6 | 6.3 |
| Site of infection, % | ||
| lower extremity | 88.6 | 89.1 |
| upper extremity | 2.3 | 7.8 |
| other | 9.1 | 3.1 |
| Treated with penicillin, % | 15.9 | 90.6 |
| Clinical end result, % | ||
| Cured | 72.7 | 90.6 |
| Cured but unplanned changes in treatmentc | 22.7 | 6.3 |
| Treatment failure | 4.6 | 3.1 |
| Clinical end result at 3 months, % | ||
| Cured | 68.2 | 85.9 |
| Cured but unplanned changes in treatmentc | 5.6 | 1.6 |
| Treatment failure | 25.0 | 12.5 |
| Missing | 2.3 | – |
| Adverse event, % | ||
| Yes | 6.8 | 1.6 |
| No | 93.2 | 98.4 |
Data retrieved from semi-structured discharge summaries available since December 2020.
Peripheral artery disease.
CRP: C-reactive protein.
The patient was considered cured with unplanned changes in the antimicrobial treatment if the iv antibiotic had to be changed during OPAT or before the 3-month evaluation due to relapse of infection, adverse event, or other causes. There were only 4 patients with adverse events (Supplementary Appendix S5). One patient died, but the cause of death was not related to erysipelas or its treatment. No other causes or eCIP malfunctions were recorded. Therefore, most cases of unplanned changes represent relapses of infection.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
